

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street analyst slashes targets due to serious trial safety signals.
You can purchase shares of ADC Therapeutics (NYSE:ADCT) through any online brokerage.
Other companies in ADC Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
ADC Therapeutics has a consensus price target of $5.75.
The stock price for ADC Therapeutics (NYSE: ADCT) is $1.3309 last updated November 13, 2026 at 7:21 PM EST.
There are no upcoming dividends for ADC Therapeutics.
ADC Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for ADC Therapeutics.
ADC Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and...